- Home
- PHAR vs EE Comparison
PHAR vs EE Comparison
Compare PHAR & EE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAR
- EE
- Stock Information
- Founded
- PHAR 1988
- EE 2003
- Country
- PHAR Netherlands
- EE United States
- Employees
- PHAR N/A
- EE N/A
- Industry
- PHAR Biotechnology: Pharmaceutical Preparations
- EE Oil/Gas Transmission
- Sector
- PHAR Health Care
- EE Utilities
- Exchange
- PHAR Nasdaq
- EE Nasdaq
- Market Cap
- PHAR 718.1M
- EE 914.5M
- IPO Year
- PHAR N/A
- EE 2022
- Fundamental
- Price
- PHAR $10.27
- EE $27.94
- Analyst Decision
- PHAR Strong Buy
- EE Hold
- Analyst Count
- PHAR 3
- EE 7
- Target Price
- PHAR $30.00
- EE $32.29
- AVG Volume (30 Days)
- PHAR 4.3K
- EE 453.2K
- Earning Date
- PHAR 07-31-2025
- EE 08-06-2025
- Dividend Yield
- PHAR N/A
- EE 0.83%
- EPS Growth
- PHAR N/A
- EE 37.63
- EPS
- PHAR N/A
- EE 1.53
- Revenue
- PHAR $320,708,000.00
- EE $966,414,000.00
- Revenue This Year
- PHAR $13.31
- EE $34.48
- Revenue Next Year
- PHAR $7.68
- EE $14.93
- P/E Ratio
- PHAR N/A
- EE $18.95
- Revenue Growth
- PHAR 24.13
- EE N/A
- 52 Week Low
- PHAR $6.65
- EE $17.54
- 52 Week High
- PHAR $12.61
- EE $32.99
- Technical
- Relative Strength Index (RSI)
- PHAR 49.06
- EE 45.46
- Support Level
- PHAR $10.46
- EE $27.78
- Resistance Level
- PHAR $11.49
- EE $29.98
- Average True Range (ATR)
- PHAR 0.34
- EE 0.86
- MACD
- PHAR -0.12
- EE -0.21
- Stochastic Oscillator
- PHAR 31.46
- EE 29.19
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.
About EE Excelerate Energy Inc.
Excelerate Energy Inc offers LNG solutions, providing integrated services along the LNG value chain. It offers a full range of regasification services, from FSRUs to infrastructure development, to LNG and natural gas supply. Its business spans the globe, with a regional presence in 11 countries and an operational presence in Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States.